Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy
Vindi Jurinović(Ludwig-Maximilians-Universität München), Robert Kridel(BC Cancer Agency), Annette M. Staiger(Robert Bosch Hospital), Monika Szczepanowski(University Hospital Schleswig-Holstein), Heike Horn(Robert Bosch Hospital), Martin Dreyling(Ludwig-Maximilians-Universität München), Andreas Rosenwald(University of Würzburg), German Ott(Robert Bosch Hospital), Wolfgang Hiddemann(University Hospital Schleswig-Holstein), Andrew D. Zelenetz(Memorial Sloan Kettering Cancer Center), Paul M. Barr(University of Rochester), Jonathan W. Friedberg(University of Rochester), Stephen M. Ansell(Mayo Clinic in Arizona), Laurie H. Sehn(BC Cancer Agency), Joseph M. Connors(BC Cancer Agency), Randy D. Gascoyne(BC Cancer Agency), Wolfgang Hiddemann(German Cancer Research Center), Michael Unterhalt(Ludwig-Maximilians-Universität München), David M. Weinstock(Dana-Farber Cancer Institute), Oliver Weigert(German Cancer Research Center)
Cited by 229Open Access
Abstract
Key Points The posttreatment end point progression of FL within 24 months (POD24) is strongly associated with OS. A pretreatment clinicogenetic risk model (m7-FLIPI) predicts POD24 and OS and identifies the smallest subgroup with highest unmet need.
Related Papers
No related papers found
Powered by citation graph analysis